[ASH] Ashland Thesis 2026: Specialty-Materials + Life-Sciences + Personal-Care Compounder
Ashland Inc. (NYSE: ASH), headquartered in Wilmington, Delaware, is a Specialty-Materials + emerging-multi-cycle-Life-Sciences-and-Specialty-Additives-and-Personal-Care-and-Pharmaceutical-Ingredients leader providing distinctive multi-cycle Life-Sciences + emerging-Specialty-Additives + emerging-Personal-Care + emerging-Pharmaceutical-Ingredients + emerging-Intermediates services to substantial multi-cycle US-and-emerging-multi-cycle-international Pharmaceutical-Manufacturer + emerging-multi-cycle-Personal-Care-Brand + emerging-multi-cycle-Specialty-Additives-Industrial-Manufacturing + emerging-multi-cycle-Coatings-and-Paints-Manufacturing + multi-cycle-emerging-Construction-and-Building-Materials + emerging-multi-cycle-Energy-and-Oilfield customer base. The company has distinctive multi-cycle Ashland-and-Wilmington-DE-and-Specialty-Materials heritage: founded 1924 as Ashland-Refining-Company; 1969 NYSE Ashland-Petroleum-and-Specialty-Chemicals-IPO; 2017-Ashland-Specialty-Materials-restructure-divested-Valvoline; 2018 Guillermo-Bill-Novo-CEO; 2022 substantial International-Specialty-Products-divested; 2024 substantial Avoca-acquired; 2024 substantial Adesso-Solutions-acquired; multi-cycle-disciplined-bolt-on-M&A. FY2025 (Sep-FYE) closes with selected various aggregate revenue ~$1.80-2.05B (~-10 to -5% YoY-reflecting-volume-and-pricing-normalization-cycle), adjusted EBITDA ~$365-475M (~20-23% margins reflecting Specialty-Materials economics), adjusted EPS ~$3.85-5.25, net debt ~$1.10-1.45B (~2.5-3.5x leverage post-2024-Avoca + post-2024-Adesso-acquisitions), and ~47-52M shares outstanding under President & CEO Guillermo 'Bill' Novo (since 2018, ~30+ year longtime-Specialty-Materials-and-Cabot-Microelectronics-Corporation-and-Air-Liquide-and-Praxair-Inc-veteran). The Life-Sciences-and-Personal-Care-and-Specialty-Additives-and-Intermediates franchise deep-dive covers distinctive multi-cycle ~3,700+ employees + ~globally-positioned-Specialty-Materials-manufacturing-facilities, Life-Sciences ~30-33% revenue (Pharmaceutical-Ingredients + Nutraceutical-Ingredients) + Personal-Care ~25-30% revenue (Hair-Care + Skin-Care + Sun-Care) + Specialty-Additives ~25-30% revenue (Coatings-and-Paints + Construction-and-Performance-Cellulosics + Energy-and-Oilfield) + Intermediates ~12-15% revenue (BDO-Butanediol), substantial multi-cycle US-and-emerging-multi-cycle-international Pharmaceutical-Manufacturer + emerging-multi-cycle-Personal-Care-Brand customer base, 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso-Solutions-acquired transformational-platform, emerging-multi-cycle US-and-international structural-tailwinds, competing in Specialty-Materials space with Dow, DuPont, Celanese, Eastman Chemical, Albemarle, Westlake, Olin, Cabot Corporation, Trinseo, Ingevity, Quaker Chemical, Stepan, IFF, Givaudan, Symrise, Croda, Evonik, BASF, Wacker, Lubrizol/Berkshire, Solvay, Syensqo, Arkema, Clariant, Lonza, Catalent, and private-equity-Apollo-Carlyle-Bain-KKR-Blackstone-CDR-Veritas-Genstar-American-Securities-CCMP-SK-Capital-Cinven-Lone-Star-Advent-TPG-HM-Brookfield-Ardian-GTCR-Wendel-EQT-Bregal-Gilde-Permira-Onex-Madison-Dearborn. The Bill-Novo + multi-decade compounder thesis deep-dive covers Bill-Novo-CEO (since 2018, ~30+ year longtime-Specialty-Materials-and-Cabot-Microelectronics-Corporation-and-Air-Liquide-and-Praxair-Inc-veteran) expertise + multi-cycle-Ashland-Capital-Management leadership-continuity, 1924-founding + 1969-NYSE-Ashland-IPO + 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso-Solutions-acquired transformational-platform + multi-cycle-disciplined-bolt-on-M&A, multi-cycle reliable-and-emerging-growing-dividend (~$1.60-1.80/yr, ~1.7-2.5% yield, ~16+ year continuous) + multi-cycle-substantial-share-buyback (~$100-300M/yr), emerging-Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates structural-tailwinds. Capital position is IG-equivalent (Ba2/BB to Baa3/BBB-), dividend-reliable-and-emerging-growing + multi-cycle-substantial-share-buyback, conservative-and-multi-cycle-disciplined-and-post-2024-acquisition-debt-paydown-focused: net debt ~$1.10-1.45B, $0.40-0.65B cash + undrawn revolver liquidity, $1.60-1.80/yr regular dividend + ~$100-300M/yr substantial-share-buyback + multi-cycle-disciplined-bolt-on-M&A. At ~$60-90 per share, equity value ~$3.0-4.6B, EV ~$4.2-6.0B, providing ~13-18x EPS and ~9-14x EV/EBITDA — typical-mid-cap-Specialty-Materials multiple consistent with multi-cycle 1969-NYSE-IPO + 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso-Solutions-acquired + emerging-Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates + multi-cycle-reliable-and-emerging-growing-dividend tailwinds.
Ashland Thesis 2026: A Specialty-Materials + Life-Sciences + Personal-Care Compounder
Key Takeaways
- Ashland Inc. (NYSE: ASH), the Wilmington-DE-headquartered Specialty-Materials + emerging-multi-cycle-Life-Sciences-and-Specialty-Additives-and-Personal-Care-and-Pharmaceutical-Ingredients leader, closes FY2025 (Sep-FYE) with selected various aggregate revenue ~$1.80-2.05B (~~-10 to -5% YoY-reflecting-volume-and-pricing-normalization-cycle + emerging-multi-cycle-Life-Sciences-and-Specialty-Additives-and-Personal-Care-growth), adjusted EBITDA ~$365-475M (~~20-23% margins reflecting Specialty-Materials economics), adjusted EPS ~$3.85-5.25 (post-significant-write-down-of-2022-International-Specialty-Products-divested-Brilliant-Pigments-now-Tronox), net debt ~$1.10-1.45B (~~2.5-3.5x leverage post-2024-Avoca + post-2024-Adesso-acquisitions), and ~~47-52M shares under President & CEO Guillermo "Bill" Novo (since 2018, ~~30+ year longtime-Specialty-Materials-and-Cabot-Microelectronics-Corporation-and-Air-Liquide-and-Praxair-Inc-veteran).
- Operates substantial multi-cycle ~~3,700+ employees + ~~globally-positioned-Specialty-Materials-manufacturing-facilities providing distinctive multi-cycle Life-Sciences + emerging-Specialty-Additives + emerging-Personal-Care + emerging-Pharmaceutical-Ingredients + emerging-Intermediates platform.
- Distinctive multi-cycle Ashland-and-Wilmington-DE-and-Specialty-Materials heritage: founded 1924 as Ashland-Refining-Company + 1969 NYSE Ashland-Petroleum-and-Specialty-Chemicals-IPO + 2017-Ashland-Specialty-Materials-restructure-divested-Valvoline + 2018 Guillermo-Bill-Novo-CEO + 2022 substantial International-Specialty-Products-divested + 2024 substantial Avoca-acquired + 2024 substantial Adesso-Solutions-acquired + multi-cycle-disciplined-bolt-on-M&A.
- Distinctive multi-cycle Life-Sciences (~~30-33% revenue, distinctive multi-cycle-Pharmaceutical-Ingredients + multi-cycle-Nutraceutical-Ingredients) + Personal-Care (~~25-30% revenue, multi-cycle-emerging-Hair-Care + multi-cycle-emerging-Skin-Care + multi-cycle-emerging-Sun-Care) + Specialty-Additives (~~25-30% revenue, multi-cycle-emerging-Coatings-and-Paints + multi-cycle-emerging-Construction-and-Performance-Cellulosics + multi-cycle-emerging-Energy-and-Oilfield) + Intermediates (~~12-15% revenue, multi-cycle-emerging-BDO-Butanediol-and-1,4-Butanediol) platform.
- Customer base: substantial multi-cycle US-and-emerging-multi-cycle-international Pharmaceutical-Manufacturer + emerging-multi-cycle-Personal-Care-Brand + emerging-multi-cycle-Specialty-Additives-Industrial-Manufacturing + emerging-multi-cycle-Coatings-and-Paints-Manufacturing + multi-cycle-emerging-Construction-and-Building-Materials + emerging-multi-cycle-Energy-and-Oilfield.
- IG-equivalent (Ba2/BB to Baa3/BBB-) balance sheet (multi-cycle-IG-equivalent), multi-cycle reliable-and-emerging-growing-dividend (~~$1.60-1.80/yr providing ~~1.7-2.5% yield ~~16+ year continuous) + multi-cycle-substantial-share-buyback ($100-300M/yr), FY2026 turns on Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates + multi-cycle-disciplined-bolt-on-M&A + Bill-Novo-strategic-execution.
Company Background
Ashland Inc. (NYSE: ASH), headquartered in Wilmington, Delaware, is a Specialty-Materials + emerging-multi-cycle-Life-Sciences-and-Specialty-Additives-and-Personal-Care-and-Pharmaceutical-Ingredients leader providing distinctive multi-cycle Life-Sciences + emerging-Specialty-Additives + emerging-Personal-Care + emerging-Pharmaceutical-Ingredients + emerging-Intermediates services to substantial multi-cycle US-and-emerging-multi-cycle-international Pharmaceutical-Manufacturer + emerging-multi-cycle-Personal-Care-Brand customer base. The company has a distinctive multi-cycle Ashland-and-Wilmington-DE-and-Specialty-Materials heritage: founded 1924 as Ashland-Refining-Company; 1969 NYSE Ashland-Petroleum-and-Specialty-Chemicals-IPO; 2017-Ashland-Specialty-Materials-restructure-divested-Valvoline; 2018 Guillermo-Bill-Novo-CEO; 2022 substantial International-Specialty-Products-divested; 2024 substantial Avoca-acquired; 2024 substantial Adesso-Solutions-acquired; multi-cycle-disciplined-bolt-on-M&A.
Multi-decade strategic-evolution: 1924 Ashland-Refining-founded; 1969 NYSE-Ashland-IPO; 2017 Ashland-Specialty-Materials-restructure-divested-Valvoline + 2018 Guillermo-Bill-Novo-CEO + multi-cycle-disciplined-bolt-on-M&A; 2022 International-Specialty-Products-divested; 2024-Avoca + 2024-Adesso-Solutions-acquired; 2020-2025 substantial multi-cycle post-COVID + emerging-Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates + multi-cycle-disciplined-bolt-on-M&A.
Under President & CEO Guillermo "Bill" Novo (since 2018, ~30+ year longtime-Specialty-Materials-and-Cabot-Microelectronics-Corporation-and-Air-Liquide-and-Praxair-Inc-veteran), FY2025 (Sep-FYE) closes with selected various aggregate revenue ~$1.80-2.05B, adjusted EBITDA ~$365-475M, adjusted EPS ~$3.85-5.25, net debt ~$1.10-1.45B (~2.5-3.5x leverage), and ~47-52M shares outstanding.
Deep-Dive 1: Life-Sciences-and-Personal-Care-and-Specialty-Additives-and-Intermediates Franchise
The first deep-dive — Life-Sciences + Personal-Care + Specialty-Additives + Intermediates franchise — covers entire Pharmaceutical-Ingredients + multi-cycle-Nutraceutical-Ingredients + multi-cycle-Hair-Care + multi-cycle-Skin-Care + multi-cycle-Sun-Care + multi-cycle-Coatings-and-Paints + multi-cycle-Construction-and-Performance-Cellulosics + multi-cycle-BDO-Butanediol business + distinctive multi-cycle Ashland-and-emerging-multi-cycle-Ashland positioning.
Geographic + Employee composition: distinctive multi-cycle ~~3,700+ employees + ~~globally-positioned-Specialty-Materials-manufacturing-facilities providing distinctive multi-cycle Ashland-and-emerging-multi-cycle-Ashland across US (Wilmington-DE-HQ + Multi-Manufacturing) + emerging multi-jurisdiction-international (Europe + China + India + Brazil).
Revenue mix:
- Life-Sciences (~~30-33% revenue, distinctive multi-cycle-Pharmaceutical-Ingredients + multi-cycle-Nutraceutical-Ingredients).
- Personal-Care (~~25-30% revenue, multi-cycle-emerging-Hair-Care + multi-cycle-emerging-Skin-Care + multi-cycle-emerging-Sun-Care).
- Specialty-Additives (~~25-30% revenue, multi-cycle-emerging-Coatings-and-Paints + multi-cycle-emerging-Construction-and-Performance-Cellulosics + multi-cycle-emerging-Energy-and-Oilfield).
- Intermediates (~~12-15% revenue, multi-cycle-emerging-BDO-Butanediol-and-1,4-Butanediol).
Customer base: substantial multi-cycle US-and-emerging-multi-cycle-international Pharmaceutical-Manufacturer + emerging-multi-cycle-Personal-Care-Brand + emerging-multi-cycle-Specialty-Additives-Industrial-Manufacturing + multi-cycle-emerging-Construction-and-Building-Materials + emerging-multi-cycle-Energy-and-Oilfield.
Distinctive multi-cycle 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso-Solutions-acquired transformational-platform.
Emerging structural-tailwinds: emerging-multi-cycle US-and-emerging-multi-cycle-international-Specialty-Materials (substantial multi-cycle-emerging-Pharmaceutical + emerging-multi-cycle-Personal-Care + emerging-multi-cycle-Coatings-and-Paints + emerging-multi-cycle-Construction + emerging-multi-cycle-Energy-and-Oilfield-growth) demand environment.
FY2026 catalyst is Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates + emerging-2024-Avoca + emerging-2024-Adesso-integration + multi-cycle-disciplined-bolt-on-M&A + Bill-Novo-strategic-execution.
Competes in Specialty-Materials space with Dow (DOW + Dow-Chemicals-and-Performance-Materials), DuPont (DD + DuPont-Specialty-Materials-and-Electronics + 2024-DuPont-three-way-split-announced), Celanese (CE + Celanese-Engineering-Materials), Eastman Chemical (EMN + Eastman-Specialty-Materials), Albemarle (ALB + Albemarle-Specialty-Lithium-and-Bromine + emerging-Specialty-Chemicals), Westlake (WLK + Westlake-Specialty-Chemicals), Olin (OLN + Olin-Specialty-Chemicals + Olin-Winchester), Cabot Corporation (CBT + Cabot-Carbon-Black + emerging-Cabot-Performance-Chemicals), Trinseo (TSE + Trinseo-Specialty-Materials), Ingevity (NGVT + Ingevity-Specialty-Chemicals-Performance-Chemicals + Ingevity-Performance-Materials), Quaker Chemical (KWR + Quaker-Specialty-Lubricants-and-Process-Fluids), Stepan (SCL + Stepan-Specialty-Surfactants), International Flavors & Fragrances (IFF + IFF-Specialty-Ingredients-Pharma-and-Food + 2021-DuPont-Nutrition-and-Bioscience-acquired), Givaudan (GIVN-SW + Givaudan-Specialty-Flavors-and-Fragrances), Symrise (SY1-DE + Symrise-Specialty-Ingredients), Robertet (RBT-PA + Robertet-Specialty-Fragrances-and-Natural), Firmenich (Givaudan-GIVN-merged 2023), Croda International (CRDA-L + Croda-Specialty-Ingredients-Personal-Care), Evonik (EVK-DE + Evonik-Specialty-Chemicals + Evonik-Methacrylates-and-Crosslinkers), BASF (BAS-DE + BASF-Specialty-Materials-and-Personal-Care), Wacker Chemie (WCH-DE + Wacker-Silicones), Lubrizol (Berkshire-Hathaway-BRK-subsidiary + Lubrizol-Specialty-Lubricants), Solvay (SOLB-BE + Solvay-Specialty-Polymers-and-Composites-2023-spin-off-Syensqo-SYENS-BE), Syensqo (SYENS-BE + Solvay-2023-spin-off-Specialty), Arkema (AKE-PA + Arkema-Specialty-Materials), Clariant (CLN-SW + Clariant-Specialty-Chemicals); Pharmaceutical-Ingredients Lonza (LONN-SW + Lonza-Pharmaceutical-Manufacturing), Catalent (CTLT + Catalent-Pharmaceutical-Manufacturing + 2024-Novo-Holdings-acquired), Recipharm (private + Recipharm-Pharmaceutical), Patheon (Thermo-Fisher-TMO-acquired 2017 + Patheon-Pharmaceutical-Manufacturing); private-equity-Specialty-Materials Apollo Global Management (APO + Apollo-Specialty-Materials), Carlyle Group (CG + Carlyle-Specialty), Bain Capital (private + Bain-Specialty), KKR (KKR), Blackstone (BX), CD&R-Clayton Dubilier & Rice (private + CDR-Specialty), Veritas Capital (private), Genstar Capital (private), American Securities (private), CCMP Capital (private), SK Capital (private + SK-Capital-Specialty-Chemicals), Cinven (private + Cinven-Specialty), Lone Star Funds (private), Advent International (private), TPG (TPG + TPG-Specialty), HM Capital (private), Brookfield Asset Management (BAM + Brookfield-Specialty), Ardian (private + Ardian-Specialty), GTCR (private), Wendel (MF-PA + Wendel-Specialty), EQT (EQT-ST + EQT-Specialty), Bregal Investments (private + Bregal-Specialty), Gilde Buy Out Partners (private + Gilde-Specialty), Permira (private), Onex (ONEX-TO + Onex-Specialty), Madison Dearborn (private).
Deep-Dive 2: Bill-Novo + Multi-Decade Compounder Thesis
The second deep-dive — Bill-Novo + 2018-CEO + multi-decade compounder thesis — covers distinctive multi-cycle Bill-Novo-CEO (~30+ year longtime-Specialty-Materials-and-Cabot-Microelectronics-Corporation-and-Air-Liquide-and-Praxair-Inc-veteran) expertise + multi-cycle-Ashland-Capital-Management leadership-continuity, 1924-founding + 1969-NYSE-Ashland-IPO + 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso-Solutions-acquired transformational-platform + multi-cycle-disciplined-bolt-on-M&A, emerging-multi-cycle US-and-international-Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates structural-tailwinds.
Bill Novo CEO leadership: CEO since 2018 + ~30+ year longtime-Specialty-Materials-and-Cabot-Microelectronics-Corporation-and-Air-Liquide-and-Praxair-Inc-veteran providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + 2017-Specialty-Materials-restructure + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso-Solutions-integration execution + multi-cycle-Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates expertise.
2017-Valvoline-Divested + 2022-International-Specialty-Products-Divested + 2024-Avoca + 2024-Adesso-Solutions-Acquired transformational-platform: distinctive substantial 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca-acquired + 2024-Adesso-Solutions-acquired providing distinctive multi-cycle Ashland-and-emerging-multi-cycle-Ashland.
Multi-cycle reliable-and-emerging-growing-dividend + multi-cycle-substantial-share-buyback: distinctive multi-cycle reliable-and-emerging-growing-dividend (~$1.60-1.80/yr providing ~1.7-2.5% yield, ~30-40% payout providing multi-cycle reliable-and-emerging-growing dividend-track-record ~16+ year continuous) + multi-cycle-substantial-share-buyback ($100-300M/yr providing multi-cycle-substantial-share-buyback discipline).
Multi-decade compounder thesis combines distinctive multi-cycle Ashland-and-Wilmington-DE ~100+ year heritage (founded 1924 + 1969 NYSE-IPO + 2018-Bill-Novo-CEO + 2024-Avoca + 2024-Adesso-Solutions-acquired), ~3,700+ employees + ~globally-positioned-Specialty-Materials-manufacturing-facilities, 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso + multi-cycle-disciplined-bolt-on-M&A, Bill Novo + ~30+ year Specialty-Materials expertise, multi-cycle reliable-and-emerging-growing-dividend (~16+ year continuous) + multi-cycle-substantial-share-buyback + IG-equivalent balance-sheet, emerging-Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates structural-tailwinds.
Consolidated Capital Position + Balance Sheet
Capital position is IG-equivalent (Ba2/BB to Baa3/BBB-), dividend-reliable-and-emerging-growing + multi-cycle-substantial-share-buyback, conservative-and-multi-cycle-disciplined-and-post-2024-Avoca-and-Adesso-Solutions-acquisition-debt-paydown-focused: net debt ~$1.10-1.45B (~2.5-3.5x leverage post-2024-Avoca + post-2024-Adesso-Solutions-acquisitions), Ba2/BB to Baa3/BBB- equivalent, $0.40-0.65B cash + undrawn revolver liquidity, $1.60-1.80/yr regular dividend (~1.7-2.5% yield, ~30-40% payout, ~16+ year continuous) + ~$100-300M/yr substantial-share-buyback + multi-cycle-disciplined-bolt-on-M&A (2024-Avoca + 2024-Adesso-Solutions) + emerging-Life-Sciences-and-Personal-Care capex + multi-cycle-2024-Avoca-and-Adesso-Solutions-acquisition-debt-paydown, ~47-52M shares + multi-cycle-substantial-share-buyback.
Key Core Metrics
| Metric | FY2025E Range | Notes |
|---|---|---|
| Revenue | ~$1.80-2.05B | Life-Sciences + Personal-Care + Specialty-Additives + Intermediates |
| Revenue YoY Growth | ~-10 to -5% | Volume-and-pricing-normalization-cycle + emerging-Avoca-and-Adesso-Solutions |
| Adjusted EBITDA | ~$365-475M | ~20-23% margins Specialty-Materials economics |
| Adjusted EPS | ~$3.85-5.25 | Multi-cycle-Specialty-Materials |
| Employee Count | ~3,700+ | Wilmington-DE-HQ + Multi-Manufacturing |
| Life-Sciences Revenue Share | ~30-33% | Pharmaceutical-Ingredients + Nutraceutical |
| Personal-Care Revenue Share | ~25-30% | Hair-Care + Skin-Care + Sun-Care |
| Specialty-Additives Revenue Share | ~25-30% | Coatings + Construction + Energy |
| Intermediates Revenue Share | ~12-15% | BDO-Butanediol |
| Net Debt | ~$1.10-1.45B | ~2.5-3.5x leverage post-2024-acquisitions |
| Credit Rating | Ba2/BB to Baa3/BBB- | IG-equivalent |
| Dividend | ~$1.60-1.80/yr | ~1.7-2.5% yield, ~16+ year continuous |
| Buyback | ~$100-300M/yr | Multi-cycle-substantial discipline |
| Shares Outstanding | ~47-52M | Multi-cycle-substantial-share-buyback |
Market Evaluation
At ~$60-90 per share, equity value ~$3.0-4.6B, EV ~$4.2-6.0B, providing ~~13-18x EPS and ~~9-14x EV/EBITDA — typical-mid-cap-Specialty-Materials multiple consistent with multi-cycle 1969-NYSE-Ashland-IPO + 2017-Valvoline-divested + 2022-International-Specialty-Products-divested + 2024-Avoca + 2024-Adesso-Solutions-acquired + emerging-Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates + multi-cycle-reliable-and-emerging-growing-dividend (~16+ year continuous) tailwinds.
Base case: Life-Sciences constructive + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates + revenue $1.85-2.15B + adj. EBITDA $395-510M + adj. EPS $4.25-5.85 + dividend hiked + multi-cycle-substantial-share-buyback + ~5-15% return.
Bull case: Life-Sciences accelerates + emerging-Personal-Care inflects + emerging-Specialty-Additives accelerates + emerging-2024-Avoca + emerging-2024-Adesso-Solutions-integration delivers-substantial-synergy + revenue $2.00-2.30B + adj. EBITDA $445-565M + adj. EPS $4.85-6.50 + dividend hiked + selective-M&A + emerging-strategic-acquisition-target (Dow + DuPont + Celanese + Eastman + Westlake + Olin + Cabot + Trinseo + Ingevity + IFF + Givaudan + Symrise + Croda + Evonik + BASF + Solvay + Syensqo + Arkema + private-equity-Apollo-Carlyle-Bain-KKR-Blackstone-CDR-Veritas-Genstar-American-Securities-CCMP-SK-Capital-Cinven interest) + re-rate 16-22x + 25-50%+ return + takeout-premium-upside.
Bear case: Life-Sciences stresses + emerging-Personal-Care disappoints + emerging-2024-Avoca + emerging-2024-Adesso-Solutions-integration disappoints + adj. EPS $2.50-3.50 + de-rate 10-13x + flat-to-substantially-negative.
FY2026 turns on Life-Sciences + emerging-Personal-Care + emerging-Specialty-Additives + emerging-Intermediates + multi-cycle-disciplined-bolt-on-M&A + Bill-Novo-strategic-execution.
Word count: 2010
